natgillin/translations-raw huggingface dataset:
Dynastat should not be used during the first two trimesters of pregnancy unless clearly necessary (i. e. the potential benefit to the patient outweighs the potential risk to the foetus).
Dynastata ne smemo uporabljati v prvih dveh trimesečjih nosečnosti, razen če je nujno potrebno (če pričakovana korist za bolnico odtehta potencialno tveganje za plod).
Parecoxib, valdecoxib (its active metabolite) and a valdecoxib active metabolite are excreted in the milk of rats.
Dojenje Parekoksib, valdekoksib (njegov aktivni presnovek) in aktivni presnovek valdekoksiba se pri podganah izločajo v mleku.
It is not known whether valdecoxib is excreted in human milk.
Ni znano, ali se valdekoksib izloča s človeškim mlekom.
Dynastat should not be administered to women who breast-feed (see sections 4.3 and 5.3).
(glejte poglavji 4. 3 in 5. 3).
No studies on the effect of Dynastat on the ability to drive or use machines have been performed.
Študije o vplivu na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
However, patients who experience dizziness, vertigo or somnolence after receiving Dynastat should refrain from driving or operating machines.
Vendar bolniki, ki imajo po prejemu Dynastata omotico, vrtoglavico ali zaspanost, ne smejo voziti ali upravljati s stroji.
Of the Dynastat treated patients in controlled trials, 1962 were patients with post-surgical pain.
V kontrolirane raziskave zdravljenja z Dynastatom, je bilo poleg drugih, vključenih 1962 bolnikov s pooperacijskimi bolečinami.
The following undesirable effects had a rate greater than placebo and have been reported among 1543 patients administered Dynastat 20 or 40 mg as a single or multiple dose (up to 80 mg/ day) in 12 placebo controlled studies, including dental, gynaecologic, orthopaedic surgery or coronary artery bypass graft surgery as well as pre-operative administration in dental and orthopaedic surgeries.
Te raziskave so vključevale stomatološke, ginekološke in ortopedske operacije, obvod na koronarnih arterijah ter predoperacijsko uporabo pred stomatološkimi in ortopedskimi posegi.
The discontinuation rate due to adverse events in these studies was 5.0% for patients receiving Dynastat and 4.3% for patients receiving placebo.
Delež prekinitev zaradi neželenih učinkov je bil v teh raziskavah 5, 0% pri bolnikih, ki so dobivali Dynastat, in 4, 3% pri tistih, ki so dobivali placebo.
7 [Very Common (≥ 1/ 10), Common (≥ 1/ 100, < 1/ 10) Uncommon (≥ 1/ 1000, < 1/ 100) Rare (≥ 1/ 10,000, < 1/ 1000) Very rare (< 1/ 10,000) not known (cannot be estimated from the available data)]
[Zelo pogosto (≥ 1/ 10), pogosto (≥ 1/ 100, < 1/ 10), občasno (≥ 1/ 1. 000, < 1/ 100), redko (≥ 1/ 10. 000, < 1/ 1. 000), zelo redko (< 1/ 10. 000), ni znano (ni mogoče oceniti iz podatkov, ki so na voljo)]
Infections and infestations Uncommon: abnormal sternal serous wound drainage, wound infection.
7 Infekcijske in parazitske bolezni Občasno: nenormalen serozen izcedek iz sternalne rane, okužba rane
Blood and lymphatic system disorders Common: post-operative anaemia Uncommon: thrombocytopenia
Bolezni krvi in limfatičnega sistema Pogosto: pooperacijska anemija Občasno: trombocitopenija
Metabolism and nutrition disorders Common: hypokalaemia
Presnovne in prehranske motnje Pogosto: hipokaliemija
Pyschiatric disorders:
Psihiatrične motnje:
Common: agitation, insomnia
Pogosto: agitiranost, nespečnost
Nervous system disorders Common: hypoaesthesia Uncommon: cerebrovascular disorder
Bolezni živčevja Pogosti: hipestezija Občasno: cerebrovaskularne motnje
Cardiac disorders Uncommon: bradycardia
Srčne bolezni Občasno: bradikardija
Vascular disorders Common: hypertension, hypotension Uncommon: aggravated hypertension
Žilne bolezni Pogosto: hipertenzija, hipotenzija Občasno: poslabšanje hipertenzije
Respiratory, thoracic and mediastinal disorders Common: respiratory insufficiency, pharyngitis
Bolezni dihal, prsnega koša in mediastinalnega prostora Pogosto: respiracijska insuficienca, faringitis
Gastrointestinal disorders Common: alveolar osteitis (dry socket), dyspepsia, flatulence Uncommon: gastroduodenal ulceration
Bolezni prebavil Pogosto: alveolarni osteitis ("suha jamica"), dispepsija, flatulenca Občasno: gastroduodenalne razjede
Skin and subcutaneous tissue disorders Common: pruritus Uncommon: ecchymosis
Bolezni kože in podkožja Pogosto: srbenje Občasno: ekhimoze
Musculoskeletal and connective tissue disorders Common: back pain
Bolezni kosti, sklepov, mišic in vezivnega tkiva Pogosto: bolečine v hrbtu
Renal and urinary disorders Common: oliguria
Bolezni sečil Pogosto: oligurija
General disorders and administration site conditions Common: peripheral oedema
Splošne težave in spremembe na mestu aplikacije Pogosto: periferni edemi
SGOT increased, SGPT increased, blood urea nitrogen increased.
Preiskave Pogosto: zvišanje kreatinina v krvi Občasno: zvišanje SGOT, zvišanje SGPT, zvišanje sečnine
The following rare, serious adverse events have been reported in association with the use of NSAIDs and cannot be ruled out for Dynastat: bronchospasm and hepatitis.
Naslednji redki, resni neželeni učinki so bili opisani med uporabo nesteroidnih protivnetnih zdravil in jih pri Dynastatu ni mogoče izključiti: bronhospazem in hepatitis.
Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse events, such as cardiovascular/ thromboembolic events, deep surgical infections and sternal 8 wound healing complications.
Po obvodni operaciji koronarnih arterij bolnike, ki dobijo Dynastat, bolj ogrožajo neželeni učinki, npr. kardiovaskularni/ tromboembolični dogodki, globoke kirurške okužbe in zapleti na sternalni rani.
Cardiovascular/ thromboembolic events include myocardial infarction, stroke/ TIA, pulmonary embolus and deep vein thrombosis (see section 4.3 and 5.1).
Kardiovaskularni/ tromboembolični dogodki vključujejo miokardni infarkt, kap/ TIA, pljučno embolijo in globoko vensko trombozo (glejte poglavji 4. 3 in 5. 1).
Rare: acute renal failure, renal failure, myocardial infarction, congestive heart failure, abdominal pain, nausea, vomiting, dyspnoea, tachycardia and Stevens-Johnson syndrome.
8 Redko: akutna odpoved ledvic, odpoved ledvic, miokardni infarkt, kongestivno srčno popuščanje, abdominalna bolečina, navzea, bruhanje, dispneja, tahikardija in Stevens- Johnsonov sindrom.
Very rare: erythema multiforme, exfoliative dermatitis and hypersensitivity reactions including anaphylaxis and angioedema (see section 4.4).
Zelo redko: multiformni eritem, eksfoliativni dermatitis in preobčutljivostne reakcije, vključno z anafilaktičnimi reakcijami in angioedemom (glejte poglavje 4. 4).
In post marketing experience, the following reaction has been reported in association with the use of valdecoxib, and cannot be ruled out for parecoxib: toxic epidermal necrolysis (see section 4.4).
V obdobju po pridobitvi dovoljenja za promet je bila v zvezi z uporabo valdekoksiba opisana naslednja reakcija, ki je ni mogoče izključiti tudi pri parekoksibu: toksična epidermalna nekroliza (glejte poglavje 4. 4).
No case of parecoxib overdose has been reported.
Ni poročil o primerih prevelikega odmerjanja.
Coxib, ATC code:
Farmakoterapevtska skupina: koksib, oznaka ATC:
Valdecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range.
Parekoksib je predzdravilo valdekoksiba. Valdekoksib v območju kliničnih odmerkov selektivno zavira ciklooksigenazo- 2 (COX- 2).
Two isoforms, COX-1 and COX-2, have been identified.
Ugotovljeni sta dve izoobliki, COX- 1 in COX- 2.
COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever.
COX- 2 je tista izooblika encima, za katero je dokazano, da jo inducirajo proinflamacijski stimuli; domnevno je ta izooblika odgovorna za sintezo prostanoidnih mediatorjev bolečin, vnetja in zvišane telesne temperature.
COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function).
COX- 2 je vpletena tudi v ovulacijo, implantacijo, zaprtje ductusa arteriosusa, regulacijo delovanja ledvic in nekatere funkcije osrednjega živčevja (sprožitev zvišane telesne temperature, zaznavanje bolečin in kognitivne funkcije).
COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.
COX- 2 so pri človeku odkrili v tkivu okrog želodčnih razjed, vendar njen pomen za celjenje razjed ni ugotovljen.
The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions.
Razlika v antitrombocitni aktivnosti med nekaterimi nesteroidnimi protivnetnimi zdravili, ki zavirajo COX- 1, in selektivnimi zaviralci COX- 2 bi lahko bila klinično pomembna pri bolnikih, ki jih ogrožajo trombembolične reakcije.
COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.
Selektivni zaviralci COX- 2 zmanjšujejo tvorbo sistemskega (in s tem morda tudi endotelijskega) prostaciklina, ne da bi vplivali na trombocitni tromboksan.
The clinical relevance of these observations has not been established.
Klinični pomen teh opažanj ni ugotovljen.
The efficacy of Dynastat was established in studies of dental, gynaecologic (hysterectomy), orthopaedic (knee and hip replacement), and coronary artery bypass graft surgical pain.
Učinkovitost Dynastata so ugotovili v raziskavah operacijske bolečine pri stomatoloških, ginekoloških (histerektomija) in ortopedskih posegih (zamenjava kolka in kolena) ter obvodni operaciji koronarnih arterij.
The first perceptible analgesic effect occurred in 7 -13 minutes, with clinically meaningful analgesia demonstrated in 23-39 minutes and a peak effect within 2 hours following administration of single doses of 40 mg IV or IM Dynastat.
Prvi zaznavni analgetični učinek se je pojavil po 7 do 13 minutah, klinično pomembna analgezija pa je bila dokazana po 23 do 39 minutah, z največjim učinkom v 2 urah po uporabi posamičnih odmerkov 40 mg Dynastata intravensko ali intramuskularno.
The magnitude of analgesic effect of the 40 mg dose was comparable with that of ketorolac 60 mg IM or ketorolac 30 mg IV.
Izrazitost analgetičnega učinka 40- mg odmerka je bila primerljiva tisti po 60 mg ketorolaka intramuskularno ali 30 mg ketorolaka intravensko.
Opioid-sparing Effects:
Učinek manjše uporabe opioidov:
In a placebo-controlled, orthopedic and general surgery study (n =1050), patients received Dynastat at an initial parenteral dose of 40 mg IV followed by 20 mg twice daily for a minimum of 72 hours in addition to receiving standard care including supplemental patient controlled opioids.
V študiji na področju ortopedije in splošne kirurgije (n = 1050), ki je bila nadzorovana s placebom, so bolniki prejeli Dynastat v začetnem parenteralnem odmerku 40 mg i. v., kateremu je sledil odmerek 20 mg dvakrat na dan, najmanj 72 ur.
The reduction in opioid use with Dynastat treatment on Days 2 and 3 was 7.2 mg
Poleg tega so dobivali standardno oskrbo, vključno z dodatnimi opioidi, ki jih je uravnaval bolnik.
9 and 2.8 mg (37% and 28% respectively). This reduction in opioid use was accompanied by significant reductions in patient-reported opioid symptom distress.
Hkrati je bilo ugotovljeno dodatno olajšanje bolečine v primerjavi s samimi opioidi.
Added pain relief compared to opioids alone was shown.
Pri uporabi
Additional studies in other surgical settings provided similar observations. There are no data indicating less overall adverse events associated with the use of parecoxib compared to placebo when used in conjunction with opioids.
9 parekoksiba v primerjavi s placebom niso zasledili podatkov, ki bi ob sočasnem jemanju opioidov nakazovali povezavo z manjšo prisotnostjo celotnih neželenih učinkov.
Gastrointestinal studies:
Raziskave vpliva na prebavila:
In short-term studies (7 days), the incidence of endoscopically observed gastroduodenal ulcers or erosions in healthy young and elderly (≥ 65 years) subjects administered Dynastat (5-21%), although higher than placebo (5-12%), was statistically significantly lower than the incidence observed with NSAIDs (66-90%).
V kratkoročnih (7 dni) raziskavah je bila incidenca endoskopsko ugotovljenih gastroduodenalnih razjed ali erozij pri zdravih mladih in starejših (≥65 let) preiskovancih, ki so dobili Dynastat (5 do 21%), sicer večja kot pri placebu (5 do 12%), vendar statistično značilno manjša kot ob nesteroidnimih protivnetnih zdravilih (66– 90%).
CABG post-operative Safety Studies:
CABG študije varnosti po operacijah:
In addition to routine adverse event reporting, pre-specified event categories, adjudicated by an independent expert committee, were examined in two placebo- controlled safety studies in which patients received parecoxib sodium for at least 3 days and then were transitioned to oral valdecoxib for a total duration of 10-14 days.
Poleg rutinskega poročanja o neželenih učinkih so v dveh s placebom kontroliranih študijah varnosti raziskali vnaprej opredeljene kategorije pojavov, ki jih je presojal odbor neodvisnih strokovnjakov.
All patients received standard of care analgesia during treatment Patients received low-dose acetylsalicylic acid prior to randomization and throughout the two CABG surgery studies.
Vsi bolniki so bili med zdravljenjem deležni standardne analgezije.
The first CABG surgery study evaluated patients treated with IV parecoxib sodium 40 mg bid for a minimum of 3 days, followed by treatment with valdecoxib 40 mg bid (parecoxib sodium/ valdecoxib group) (n=311) or placebo/ placebo (n=151) in a 14-day, double-blind placebo-controlled study.
V prvi študiji CABG so ocenjevali bolnike, ki so jih zdravili s IV parekoksibom natrijem 40 mg najmanj 3 dni, čemur je sledilo zdravljenje z valdekoksibom 40 mg dvakrat dnevno (parekoksib natrij/ skupina valdekoksib (n = 311) ali prejemanje placeba/ placeba (n = 151) v 14- dnevni dvojno slepi študiji, nadzirani s placebom.
Nine pre-specified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/ dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non-infectious pulmonary complications, and death).
Ocenjevali so devet vnaprej določenih kategorij neželenih dogodkov (kardiovaskularni/ trombembolični dogodki, perikarditis, ponovni pojav poslabšanja kongestivne odpovedi srca, odpoved/ slabo delovanje ledvic, zapleti z razjedami v zgornjih prebavilih, močne krvavitve ne v GI traktu, infekcije, neinfektivni pulmonalni zapleti in smrt).
There was a significantly (p < 0.05) greater incidence of cardiovascular/ thromboembolic events (myocardial infarction, ischemia, cerebrovascular accident, deep vein thrombosis and pulmonary embolism) detected in the parecoxib/ valdecoxib treatment group compared to the placebo/ placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively).
1, 3%).
Surgical wound complications (most involving the sternal wound) were observed at an increased rate with parecoxib/ valdecoxib treatment.
Pri zdravljenju s parekoksibom/ valdekoksibom so opazili več zapletov v zvezi s kirurškimi ranami (največkrat v zvezi z rano prsnice).
In the second CABG surgery study, four pre-specified event categories were evaluated (cardiovascular/ thromboembolic; renal dysfunction/ renal failure; upper GI ulcer/ bleeding; surgical wound complication).
V drugi študiji v zvezi z operativnim posegom CABG so ocenjevali štiri vnaprej določene kategorije dogodkov (kardiovaskularni/ trombembolični, slabo delovanje/ odpoved ledvic, razjeda v zgornjih prebavilih/ krvavenje, zapleti v zvezi s kirurško rano).
Patients were randomized within 24-hours post-CABG surgery to: parecoxib initial dose of 40 mg IV, then 20 mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20 mg Q12H) (n=544) for the remainder of a 10 day treatment period; placebo IV followed by valdecoxib PO (n=544); or placebo IV followed by placebo PO (n=548).
Naključno izbrani bolniki so 24 ur po kirurškem posegu CABG prejemali: parekoksib z začetnim odmerkom 40 mg IV, nato pa 20 mg IV Q12H najmanj 3 dni, nato pa preostalih 10 dni zdravljenja še valdekoksib peroralno (20 mg Q12H) (n = 544); po prejemanju placeba IV so dobivali valdekoksib peroralno (n = 544) ali pa so po prejemanju placeba IV prejemali placebo peroralno (n = 548).
A significantly (p=0.033) greater incidence of events in the cardiovascular/ thromboembolic category was detected in the parecoxib / valdecoxib treatment group (2.0%) compared to the placebo/ placebo treatment group (0.5%).
Znatno večjo pojavnost (p = 0, 033) dogodkov v kategoriji kardiovaskularnih/ trombemboličnih obolenj so odkrili pri skupini, ki je bila zdravljena s parekoksibom/ valdekoksibom (2, 0%), v primerjavi s skupino, ki je prejemala placebo/ placebo (0, 5%).
Placebo/ valdecoxib treatment was also associated with a higher incidence of CV thromboembolic events versus placebo treatment, but this difference did not reach statistical significance.
Prejemanje placeba/ zdravljenje z valdekoksibom je bilo povezano tudi z višjo pojavnostjo kardioavskularnih/ trombemboličnih dogodkov v primerjavi s tistimi, ki so prejemali placebo, vendar ta razlika statistično ni pomembna.
Three of the six cardiovascular thromboembolic events in the placebo/ valdecoxib treatment group occurred during the placebo treatment period; these patients did not receive valdecoxib.
Ti bolniki niso prejemali valdekoksiba.
Pre-specified events that occurred with the highest incidence in all three treatment groups involved the category of surgical wound complications, including deep surgical infections and sternal wound healing events.
Vnaprej določeni dogodki, ki so se najpogosteje pojavljali v vseh treh obravnavanih skupinah, so vključevali zaplete v zvezi s kirurško rano, to je globlje ležeče infekcije kirurške rane ali zdravljenje rane na prsnici.
There were no significant differences between active treatments and placebo for any of the other pre- specified event categories (renal dysfunction/ failure, upper GI ulcer complications or surgical wound complications).
Aktivne terapije se niso značilno razlikovale od placeba glede nobene vnaprej opredeljene kategorije pojavov (moteno delovanje ledvic/ ledvična odpoved, zapleti z razjedami v zgornjih prebavilih ali zapleti kirurške rane).
General Surgery:
Študija o splošni varnosti kirurškega posega:
In a large (N=1050) major orthopedic/ general surgery trial, patients received an initial dose of parecoxib 40 mg IV, then 20 mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20 mg Q12H) (n=525) for the remainder of a 10 day treatment period, or placebo IV followed by placebo PO (n=525).
V veliki (n = 1050) pomembni raziskavi ortopedskih/ splošnih kirurških posegov so bolniki najmanj 3 dni prejemali začetni odmerek parekoksiba 40 mg IV, nato 20 mg IV Q12H, nato pa valdekoksib peroralno (20 mg Q12H) (n = 525) preostalih 10 dni obdobja zdravljenja ali pa so po prejemanju placeba IV prejemali placebo peroralno (n = 525).
There were no significant differences in the overall safety profile,
Glede profila splošne varnosti niso pri bolnikih po prestani operaciji zaznali nobene pomembne razlike, tudi ne glede vnaprej določenih kategorij, ki so opisane zgoraj v zvezi z drugo študijo operacije CABG, v zvezi s prejemanjem parekoksiba natrija/ valdekoksiba v primerjavi s prejemanjem placeba.
10 including the four pre-specified event categories described above for the second CABG surgery study, for parecoxib sodium/ valdecoxib compared to placebo treatment in these post-surgical patients.
10 Raziskave trombocitov:
In a series of small, multiple dose studies in healthy young and elderly subjects, Dynastat 20 mg or 40 mg twice daily had no effect on platelet aggregation or bleeding compared to placebo.
V več majhnih raziskavah o večkratnih odmerkih pri zdravih mladih in starejših preiskovancih so ugotovili, da 20 ali 40 mg Dynastata dvakrat na dan v primerjavi s placebom ni vplivalo na agregacijo trombocitov ali krvavitve.
In young subjects, Dynastat 40 mg twice daily had no clinically significant effect on acetylsalicylic acid -mediated inhibition of platelet function (see section 4.5).
Pri mladih preiskovancih Dynastat v odmerku 40 mg dvakrat na dan ni klinično pomembno vplival na zavrtje delovanja trombocitov z acetilsalicilno kislino (glejte poglavje 4. 5).
Absorption Exposure of valdecoxib following single doses of Dynastat, as measured by both the area under the plasma concentration vs. time curve (AUC) and peak concentration (Cmax), is approximately linear in the range of clinical doses.
Absorpcija Izpostavljenost valdekoksibu, merjena s površino pod krivuljo koncentracije v plazmi v odvisnosti od časa (AUC) in največjo koncentracijo v plazmi (Cmaks), je po enkratnih odmerkih Dynastata v območju kliničnih odmerkov približno linearna.
AUC and Cmax following twice daily administration is linear up to 50 mg IV and 20 mg IM.
AUC in Cmaks po uporabi dvakrat na dan sta linearna do 50 mg i. v. in 20 mg i. m.
Steady state plasma concentrations of valdecoxib were reached within 4 days with twice daily dosing.
Ravnotežna koncentracija valdekoksiba v plazmi je bila ob odmerjanju dvakrat na dan dosežena v 4 dneh.
Following single IV and IM doses of parecoxib sodium 20 mg, Cmax of valdecoxib is achieved in approximately 30 minutes and approximately 1 hour, respectively.
Po enkratnih i. v. ali i. m. odmerkih 20 mg natrijevega parekoksibata je Cmaks valdekoksiba dosežena v približno 30 minutah (i. v.) oz. približno 1 uri (i. m.).
Exposure to valdecoxib was similar in terms of AUC and Cmax following IV and IM administration.
Izpostavljenost valdekoksibu je bila glede na AUC in Cmaks po intravenski in intramuskularni uporabi podobna.
Average Cmax of parecoxib after IM dosing was lower compared to bolus IV dosing, which is attributed to slower extravascular absorption after IM administration.
Povprečna Cmaks parekoksiba je bila po intramuskularni uporabi manjša kot po bolusni intravenski uporabi, kar je treba pripisati počasnejši zunajžilni absorpciji po intramuskularni aplikaciji.
These decreases were not considered clinically important since Cmax of valdecoxib is comparable after IM and IV parecoxib sodium administration.
Tega zmanjšanja niso ocenili za klinično pomembno, ker je Cmaks valdekoksiba po i. m. in i. v. vnosu natrijevega parekoksibata primerljiva.
Distribution The volume of distribution of valdecoxib after its IV administration is approximately 55 litres.
Distribucija Volumen porazdelitve valdekoksiba po intravenski uporabi je približno 55 litrov.
Plasma protein binding is approximately 98% over the concentration range achieved with the highest recommended dose, 80 mg/ day.
V koncentracijskem območju, doseženem z največjim priporočenim odmerkom 80 mg/ dan, je vezava na beljakovine v plazmi približno 98%.
Metabolism Parecoxib is rapidly and almost completely converted to valdecoxib and propionic acid in vivo with a plasma half-life of approximately 22 minutes.
Presnova Parekoksib se in vivo hitro in skoraj popolnoma spremeni v valdekoksib in propionsko kislino s plazemskim razpolovnim časom približno 22 minut.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulphonamide moiety.
Izločanje valdekoksiba poteka z obsežno presnovo v jetrih, ki vključuje več poti, med drugim izoencima CYP3A4 in CYP2C9 citokroma P450 ter glukuronidacijo (okrog 20%) sulfonamidne skupine.
A hydroxylated metabolite of valdecoxib (via the CYP pathway) has been identified in human plasma that is active as a COX-2 inhibitor.
V človeški plazmi je bil ugotovljen (po poti CYP) hidroksilirani presnovek valdekoksiba, ki deluje kot zaviralec COX- 2.